A股異動 | 九安醫療漲停 2021年淨利同比增長最高近4倍至12億元
格隆匯1月20日丨 九安醫療(002432.SZ)漲停,報77.66元,總市值372億元。九安醫療1月19日披露業績預吿,預計2021年淨利潤9億元-12億元,同比增長271.4%-395.19%。2021年度繼續受全球新冠疫情影響,公司新型冠狀病毒(SARS-CoV-2)抗原家用自測OTC試劑盒產品在美國市場銷售業績大幅增長。去年前三季度,九安醫療淨利潤實現5013萬元,同比下降近九成,扣非後淨利潤尚且虧損2478萬元;結合本次業績預吿推測,意味着第四季度單季度盈利至少超過8億元,已經超過公司過往十年盈利總和。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.